Combination Therapy Using Anti-SSEA-4 Antibodies in Combination with Tumor Treatment

摘要

The present disclosure generally relates to methods and compositions of treatment comprising administering an anti-SSEA-4 antibody alone or in synergistic combination with an additive and/or other therapeutic agent in oncology to enhance therapeutic efficacy, whereby The interaction alters epitope binding of Siglec-9 proteins, including human Siglec-9 or mammalian Siglec-9, and the use of such anti-SSEA-4 compositions prevents, reduces the risk of, or prevents individuals with cancer; It relates to methods and compositions of treatment effective for treating.